Data as of October 23, 2026; trial data updated November 13, 2026
Research on CBD (cannabidiol, a non-intoxicating compound from the cannabis plant) for anxiety is mixed and low-certainty. In lab speech tests, people given one dose rated their anxiety lower than people given a placebo. In our review, 10 of 14 placebo-controlled studies in adults published before 2022, mostly single doses, reported a benefit. Of 24 published from 2022 to 2026, more of which gave CBD daily for days or weeks, 2 found lower anxiety, 3 had mixed results and 19 found no difference.
The FDA has not approved CBD for anxiety. The FDA has approved only one drug that contains CBD: Epidiolex, a prescription medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in people 1 year of age and older.
Key takeaways
- In our review, 12 of 38 placebo-controlled trials found a benefit, mostly after a single dose, and 4 had mixed or partial results. Some trials that gave CBD for days or weeks also found lower anxiety: in social anxiety disorder, anxiety disorders and high worry, and during drug or alcohol cues in people with heroin or alcohol use disorder. Most trials published since 2022 found no difference from placebo.
- Cannabidiol Life’s review of ClinicalTrials.gov counted 40 registered studies of CBD for anxiety as of October 23, 2026; 4 have posted results so far (Evidence Tracker).
- Safety and quality: CBD raised citalopram blood levels in a 2021 study of 6 patients, and the FDA warns it adds drowsiness with anxiety or sleep medicines (Anderson 2021; FDA). Product labels are not always accurate (Dowd 2025; Johnson 2025).
- Meta-analyses disagree: a 2024 analysis of 8 small CBD studies found a large but imprecise effect, and a 2025 analysis found a moderate effect for pure pharmaceutical CBD but not for CBD products pooled together, while a 2026 Lancet Psychiatry meta-analysis of 54 trials of all cannabinoids in mental and substance use disorders found no significant effect on anxiety (Wilson 2026).
- Systematic reviews: a 2022 review of 7 human studies of CBD alone, all already in our study table, found that a single dose lowered anxiety in healthy volunteers given a social-anxiety test and in people with social anxiety disorder (Fliegel 2022). A 2025 review of 49 studies of medicinal cannabis for mental health conditions found some short-term relief in anxiety after high doses of CBD, though no study in it found long-lasting effects (de Bode 2025).
On this page: What CBD is · Research · Study table · By the numbers · Types of anxiety · Why results vary · Doses in studies · CBD vs THC, CBN and CBG · Safety · Product quality · FAQ · Bottom line · How we researched this · Safety and legal information · Sources
What is CBD, and how might it affect anxiety?
CBD (cannabidiol) comes from the Cannabis sativa plant. Hemp is cannabis with very little THC (delta-9-tetrahydrocannabinol, which causes a high); marijuana has more. CBD is sold as oils, capsules, gummies, topicals and vapes.
In animal and cell studies, CBD acted on 5-HT1A, TRPV1 and CB1 receptors (Blessing 2015; endocannabinoid system). In animal research, a 2026 meta-analysis of 123 rodent studies of CBD found that it consistently reduced anxiety-like behavior compared with an inactive solution. The pooled effect across 200 results from 75 of the studies was moderate. After the authors removed outliers and adjusted for signs of publication bias, the effect was small, and they call the evidence in people limited and inconclusive (Jantsch 2026). A 2023 meta-analysis covered 120 studies, 114 in animals and 6 in people, of four compounds that boost the body’s endocannabinoid signaling, CBD among them. Pooled effects favored the compounds as a group over placebo for anxiety in animals, with one exception for a compound other than CBD, and for lab-induced anxiety in people. The authors rated the evidence quality as low, with signs of publication bias (Kwee 2023). Brain-scan studies in 10 and 15 healthy men linked a single dose of CBD to changed activity in fear areas such as the amygdala (Crippa 2004; Fusar-Poli 2009). A later scan of 24 healthy adults after one dose found no change in brain responses to emotional faces or lab-induced anxiety (Bloomfield 2022).
Does CBD help with anxiety? What the research shows
The evidence is mixed and low-certainty. Two recent meta-analyses found a benefit of CBD in at least part of their data, and a broader one did not. The broader one, a 2026 Lancet Psychiatry meta-analysis, pooled 54 trials of all cannabinoids, not only CBD, across mental and substance use disorders and found no significant effect on anxiety. A 2025 meta-analysis of 21 placebo-controlled cannabinoid trials found a moderate effect for pure pharmaceutical CBD; products with pure or enriched CBD, pooled together, were not significantly better than placebo.
A 2024 meta-analysis of 8 studies (316 people) found a large effect of CBD on anxiety, though the estimate was imprecise and its authors advised caution because the combined sample was small. Its abstract names generalized anxiety, social anxiety and PTSD and gives no doses. A 2025 systematic review of medicinal cannabis (CBD and THC products) for anxiety disorders found that 9 of the 13 studies it rated highest in quality reported improvement and 4 a negative result, and it rated the risk of bias across its 57 studies as high (Roberts 2025). The NIH’s NCCIH (page last updated 2019) says that “a small amount of evidence from studies in people suggests that cannabis or cannabinoids might help to reduce anxiety.”
The table below lists further reviews and meta-analyses that reported a benefit or a favorable signal for anxiety, as of November 13, 2026. It is a selection, not a full list. Reviews that found no significant effect on anxiety or judged the evidence insufficient are cited at the start of this section (the 2026 Lancet Psychiatry meta-analysis) and under social anxiety below (Stanciu 2021). Several of the reviews added to this page, such as Skelley 2020 and Coelho 2024, mostly summarize trials that are already in our study table, so their findings are not extra trials.
| Review | What it covered | What it reported | Its own limit |
|---|---|---|---|
| de Bode 2025 | Systematic review of 49 controlled human studies, from 15 countries, of medicinal cannabis (THC, CBD, both together, or derivatives) in people seeking help for a diagnosed mental health condition, anxiety disorders among them | Most consistently, high doses of CBD were followed by some short-term relief in anxiety (the abstract does not define a high dose) | Risk of bias was common across the studies, and no study found long-lasting effects or improvement |
| Narayan 2022 review | Systematic review of 58 studies, in healthy people and in patients, that gave CBD alone or CBD with THC and measured anxiety; it also looked at sleep | CBD’s anxiety-lowering effects were greater in healthy people and in certain clinical groups who did not use cannabis, without prominent effects on sleep; an inverted U-shaped dose curve and the ratio of CBD to THC in combined products likely shaped these effects | It says efficacy across groups, length of use, formulation and best doses remain unclear, and that more research is needed to understand how CBD works across diverse groups |
| Skelley 2020 | Systematic review of 8 articles on CBD alone (search to June 2019): 6 small randomized trials, 1 case series and 1 case report, in healthy volunteers, generalized anxiety disorder, social anxiety disorder and the anxiety part of PTSD | CBD improved outcomes on the anxiety scales the studies used and was generally well tolerated, with fatigue and sedation the most common side effects; its authors called CBD’s role in anxiety disorders promising | Few and small studies with widely varying doses; the authors say studies with standardized dosing and outcome measures are needed, and it found no studies in panic disorder, specific phobia, separation anxiety or OCD |
| Perez 2025 | Scoping review of 29 human studies (randomized trials, observational studies and case series) that reported both anxiety and sleep results for cannabis and cannabinoid products, among them CBD, THC, CBD with THC, and nabilone | Cannabinoids, particularly CBD, showed potential to improve anxiety symptoms and sleep problems; about 45% of the studies reported positive effects on both, and 15 of the 29 reported improvements in anxiety | Method limits and no standardized dosing hinder firm conclusions; of the 13 studies positive on both outcomes, 9 were case series, 9 used products with both CBD and THC, and the 1 clinical trial tested nabilone |
| Coelho 2024 | Systematic review of randomized, placebo-controlled trials of CBD for anxiety published from 2013 to 2023 (in one, a group took CBD with THC); the authors judged the trials too different to pool | The data suggest that CBD may reduce anxiety, with minimal side effects, compared with placebo | Results across anxiety types and doses were often contradictory: in its full text, 9 of the trials (60%) found no benefit from a single dose; many risk-of-bias items were unclear, and the review was not registered |
| Bahji 2020 | Meta-analysis of 14 randomized trials of cannabinoids (all cannabinoids, not CBD alone) in 1,548 adults with anxiety disorders; the abstract does not say which products the trials used or how many tested CBD | Cannabinoids reduced anxiety symptoms (standardized mean difference -1.85, 95% confidence interval -2.61 to -1.09) without causing significant adverse events, with greater effects in younger patients and with longer use; after correcting for publication bias, the overall effect was not statistically significant | Publication bias was substantial, and the authors say routine use is not supported |
| Wright 2020 | Short narrative review (not a systematic one) of animal studies and human trials of CBD alone; the abstract gives no study counts | Animal studies found anxiety-lowering, anti-stress, anti-compulsive and panic-reducing effects of CBD; early evidence from human trials in healthy volunteers and in people with social anxiety disorder suggests CBD may lower anxiety | The human evidence is preliminary; efficacy in other anxiety disorders, doses and long-term effects are not established, and most of the research used males only |
| Blessing 2015 | Narrative review of preclinical (animal and lab), human experimental, clinical and epidemiological studies of CBD | Its authors concluded that “evidence from human studies supports an anxiolytic role of CBD” (anxiolytic means anxiety-lowering) and that current evidence indicates CBD has “considerable potential” for multiple anxiety disorders | The human evidence “is currently limited to acute dosing, also with few studies in clinical populations”; the authors see a “need for further study of chronic and therapeutic effects in relevant clinical populations” |
Our count of the individual trials, updated on November 13, 2026, shows the same split and how it has changed. Of 14 placebo-controlled studies published before 2022, mostly single doses in lab tests, 10 reported a benefit (9 lower anxiety, 1 better fear-extinction learning), 3 found no difference and 1 a partial effect. Of 24 published from 2022 to 2026, more of which gave CBD daily for days or weeks and several of which were larger than any earlier trial, 2 found lower anxiety, 3 were mixed and 19 found no difference from placebo.
The 10 earlier trials that found a benefit had 10 to 60 people each, and 8 of them gave a single dose. Three of the 10 enrolled people with social anxiety disorder; the other 7 studied healthy adults or people with heroin use disorder or Parkinson’s disease. Of the eight later trials added in this update, none enrolled people for anxiety: they studied runners, active students and people with arthritis, Parkinson’s disease, insomnia or knee surgery. In seven of the eight, anxiety was a secondary, exploratory or side measure; three gave about 16 to 30 mg a day, and four were single-dose or four-dose studies.
CBD for anxiety studies: the human evidence, trial by trial
The table lists the 39 placebo-controlled studies in our review that gave people aged 18 or older CBD or a CBD-dominant product and reported anxiety results. In a crossover study, every participant took both CBD and placebo, in random order.
The counts in the research section above cover 38 of them: de Andrade Silva 2024 isn’t counted (THC unreported), and Bogenschutz 2026’s two trials count once. Eight rows were added on November 13, 2026: Vela 2022, Kanjanarangsichai 2022, McCartney 2024, Narayan 2024, Mitarnun 2025, Sahinovic 2025, Bell 2025 and Sideris 2026.
| Study | Who took part | CBD given | Result vs placebo |
|---|---|---|---|
| Anxiety disorders | |||
| Crippa 2011 | 10 with social anxiety disorder (crossover) | 400 mg once | Lower anxiety |
| Bergamaschi 2011 | 24 with social anxiety disorder | 600 mg once | Lower speech anxiety |
| Masataka 2019 | 37 people aged 18-19 with social anxiety disorder (the paper calls them teenagers) | Daily CBD oil (THC: none, per the paper) | Lower anxiety |
| Kwee 2022 | 80 with social anxiety or panic disorder | 300 mg before 8 therapy sessions | No difference |
| Gundugurti 2024 | 178 with anxiety disorders | Oral solution, 15-week study (dose not reported in the abstract) | Lower GAD-7 and HAM-A scores |
| Public speaking and other tests, healthy adults | |||
| Zuardi 1993 | 40 healthy adults | 300 mg once | Lower post-speech anxiety |
| Crippa 2004 | 10 healthy men (crossover) | 400 mg once | Lower anxiety; more sedation |
| Fusar-Poli 2009 | 15 healthy men (crossover) | 600 mg once | Non-significant trend to lower anxiety |
| Das 2013 | 48 healthy adults | 32 mg once | Better fear-extinction learning |
| Zuardi 2017 | 60 healthy adults | 100, 300 or 900 mg once | Lower post-speech anxiety at 300 mg only |
| Arndt 2017 | 38 healthy adults (crossover) | 300, 600 and 900 mg, once each | No difference |
| Hundal 2018 | 32 adults high in paranoid traits | 600 mg once | No difference; trend to more anxiety |
| Linares 2019 | 57 healthy men | 150, 300 or 600 mg once | Lower speech anxiety at 300 mg only |
| Bloomfield 2022 | 24 healthy adults (crossover) | 600 mg once | No difference |
| McCartney 2024 | 51 recreationally active adults (crossover) | 150 mg once, 90 minutes before a 10 km run | No difference |
| Leen-Feldner 2025 | 61 healthy young adults | 150, 300 or 600 mg once | No difference |
| Sahinovic 2025 | 25 trained runners (crossover) | 50 and 300 mg, once each, 1.5 hours before a run | No difference |
| Bell 2025 | 12 runners (crossover) | 300 mg once, 2 hours before a 2-mile run | Mixed: calmer and more relaxed before the run; overall anxiety score unchanged |
| Worry, test anxiety and stress | |||
| Stanley 2023 | 32 students with test anxiety | 150, 300 or 600 mg once | No difference |
| Rudisill 2023 | 40 healthy students | 300 mg once | No difference; longer attention lapses |
| Gournay 2023 | 63 adults with high worry | 50 or 300 mg/day, 2 weeks | Mixed: lower anxiety at 300 mg only; worry unchanged |
| Winkler 2025 | 180 stressed students (CBD, placebo oil or no treatment) | Full-spectrum oil up to 1 mg/kg/day, 30 days | No difference |
| PTSD and trauma | |||
| Bolsoni 2022 | 33 adults with PTSD | 300 mg once | No difference |
| Gournay 2024 | 42 trauma-exposed adults | 300 mg/day, 1 week | No significant difference |
| Anxiety alongside other health conditions | |||
| Hurd 2019 | 45 enrolled with heroin use disorder | 400 or 800 mg/day, 3 days | Less cue-induced anxiety |
| de Faria 2020 | 24 with Parkinson’s disease (crossover) | 300 mg once | Lower speech anxiety |
| Appiah-Kusi 2020 | 32 at high risk of psychosis | 600 mg/day, 1 week | Partial: between placebo and healthy levels |
| Mongeau-Perusse 2022 | 78 with cocaine use disorder | Up to 800 mg/day | No difference |
| Vela 2022 | 136 with hand osteoarthritis or psoriatic arthritis | 20-30 mg/day, 12 weeks | No difference |
| Kanjanarangsichai 2022 | 40 with Parkinson’s disease | CBD-rich extract under the tongue, average 15.59 mg CBD a day (THC 0.61 mg a day), 8 weeks | No difference |
| Hardy 2023 | 144 with advanced cancer | 50-600 mg/day, 28 days | No difference |
| Narayan 2024 | 30 with insomnia | 150 mg under the tongue nightly, 2 weeks | No difference in trait anxiety; calmer in daily ratings (second paper) |
| Nayak 2024 | 50 women with advanced breast cancer | 400 mg once | Mixed: lower anxiety 2-4 hours later only |
| Hurzeler 2025 | 22 with alcohol use disorder (crossover) | 800 mg, 3-day course (daily amount not stated in the abstract) | Lower anxiety during alcohol cues |
| Mitarnun 2025 | 60 with Parkinson’s disease | CBD-rich extract under the tongue, average 26 mg CBD a day (THC 1.2 mg a day), 12 weeks | No difference |
| Belgers 2026 | 20 with brain tumors (crossover, stopped early) | 600 mg/day, 3 weeks | No difference; placebo improved more |
| Bogenschutz 2026 | 57 with alcohol use disorder (2 trials) | 600-1,200 mg/day, 6-8 weeks | No difference |
| Sideris 2026 | 36 having both knees replaced | Prescription CBD solution, 400 or 800 mg, four doses around surgery | No difference shown: scores higher in the CBD groups after surgery, mainly at 800 mg, but also before surgery (registry NCT04749628); no test reported |
| de Andrade Silva 2024 | Root-canal patients (n not reported) | CBD-rich extract once (THC not reported) | No difference (not counted) |
Industry ties (see Sources): Gundugurti 2024, Gournay 2024, Leen-Feldner 2025, Stanley 2023, Linares 2019, Zuardi 2017, Hurd 2019, Bogenschutz 2026, Narayan 2024, McCartney 2024 and Sahinovic 2025. Not included: open-label studies, CBD-free expectancy studies and products with added THC. Smoked cannabis flower studies, such as Kayser 2020 in OCD, were also excluded from the table and counts.
CBD for anxiety by the numbers (October 2026)
| Metric | Value | Source and exact query |
|---|---|---|
| Registered studies | 40 | ClinicalTrials.gov query |
| With posted results | 4 of 40; 1 of 12 completed | Same |
| Phase 3 or 2/3 studies finished on ClinicalTrials.gov | 0 of 5; NCT07123467 (Epidiolex plus CBT for GAD) recruiting | Same |
| Largest completed trial | NCT05600114: 239 people with social anxiety disorder, completed 2023-12-13; no posted results or PubMed paper | Registry record; PubMed search |
| Most-tested types | Social anxiety, anxiety within another condition, and multi-symptom studies (anxiety one of several targets), 9 of 40 each | Same |
| PubMed papers on CBD and anxiety | 846 (10 in 2015, 144 in 2024); 69 tagged as randomized trials | PubMed query |
| US searches for “cbd for anxiety” | 6,318 a month (Oct 2025-Sep 2026), 79.0% below the 2019 average | Ahrefs (modelled estimate) |
The number of registered studies shows research interest, not whether CBD works. Method: on October 23, 2026, the ClinicalTrials.gov query in the table returned 51 records. We read every record and kept the 40 that test CBD for anxiety, leaving out 9 that did not meet our inclusion rules and counting 2 OCD studies separately. “Posted results” means results on ClinicalTrials.gov.
Cite this data: Cannabidiol Life, “CBD for Anxiety by the numbers (October 2026),” cbdoilsandedibles.com, https://cbdoilsandedibles.com/health/cbd-for-anxiety/, data as of 2026-10-23.
What studies found for each type of anxiety
- Social anxiety and public speaking: lower anxiety after single doses in speech tests (Bergamaschi 2011; Zuardi 2017) and after daily CBD oil in 37 people aged 18 to 19 with social anxiety disorder (Masataka 2019). A 2022 systematic review covered 7 human studies of CBD alone (278 people), all of them in our study table. It found that a single dose significantly lowered anxiety, without sedation, in healthy volunteers given a social-anxiety test and in people with social anxiety disorder. The one study of repeated doses also found lower social anxiety symptoms. The review rated 2 of the 7 studies at high risk of bias and 5 with some concerns (Fliegel 2022). A 2021 systematic review of 8 small randomized trials of CBD or THC in people with anxiety disorders, mood disorders or PTSD reported an improvement in all three of its CBD trials. Each was in social anxiety disorder and is in our study table. Two found lower anxiety in lab tests after a single dose (34 people), and one found modest symptom improvements after 4 weeks of daily CBD (37 people). Its authors judged the evidence insufficient and said medical cannabis should not be recommended for these disorders (Stanciu 2021). A 2026 systematic review of 18 randomized trials of medicines for adults with social anxiety disorder, published since 2015, named CBD, along with d-cycloserine, as a more recent drug showing promising results. Its abstract gives no CBD numbers and names SSRIs as the first-line medicine when cognitive behavioral therapy is unavailable (Andreoli 2026). CBD taken before 8 exposure-therapy sessions made no difference in 80 people with social anxiety or panic disorder (Kwee 2022). Three trials gave CBD to runners before a run. In a pilot of 12 runners, people rated themselves calmer (21%) and more relaxed (22%) 2 hours after 300 mg than after placebo, while their overall anxiety score did not differ (Bell 2025). Two larger trials found no difference in anxiety after 150 mg (McCartney 2024) or after 50 or 300 mg (Sahinovic 2025). No trial in our review tested stage or travel anxiety, or anxiety before a competition.
- Generalized anxiety and panic: lower GAD-7 and HAM-A scores over 15 weeks in 178 people with mild to moderate anxiety disorders, the largest published anxiety-disorder trial in our review (Gundugurti 2024); no difference in fear during a carbon-dioxide breathing challenge in 61 healthy young adults (Leen-Feldner 2025). A 2026 systematic review looked at generalized anxiety disorder, panic disorder or agoraphobia, and social anxiety disorder that had not responded to earlier care (26 randomized trials and 36 open-label studies of medicines, psychotherapy and brain stimulation). It found preliminary evidence, from open-label studies with no placebo group, for adding CBD to a person’s existing medicine. It noted mostly small samples and several method limits, and its abstract does not say how many studies tested CBD (Schiele 2026). One trial gave adults with anxiety a CBD solution under the tongue three times a day for four weeks. Its results were posted on ClinicalTrials.gov in March 2026 and are not yet peer reviewed. They show clinician-rated anxiety (HAM-A) scores falling from 21.47 to 5.13 on full-spectrum CBD (32 people) and from 23.67 to 9.67 on single-compound CBD (6 people), compared with 20.17 to 17.50 on placebo (6 people). The full-spectrum figures include 14 people from a first, open-label stage with no placebo group, and no CBD-versus-placebo test has been posted. Self-rated anxiety (BAI) fell about as much on placebo (21.00 to 8.17) as on full-spectrum CBD (20.97 to 6.88). The trial is not in our study table or counts (NCT02548559).
- Stress, worry and test anxiety: one of four trials found lower anxiety, though not less worry, and three found no difference. Single doses before a test (Stanley 2023) or in healthy students (Rudisill 2023) and 30 days of full-spectrum oil in stressed students (Winkler 2025) made no difference; the higher of two daily doses, taken for 2 weeks, lowered anxiety symptoms but not worry in 63 adults with high worry (Gournay 2023).
- PTSD and OCD: no difference after one dose in 33 adults with PTSD (Bolsoni 2022) or after a week of daily CBD in 42 trauma-exposed adults (Gournay 2024); no placebo-controlled study in our review tested CBD alone for OCD. A 2026 review of cannabinoids for PTSD found a clear benefit over placebo in 1 of 7 randomized trials, a trial of nabilone, not CBD; its two trials of a single oral dose of CBD showed minimal benefit (Aviram 2026).
- Other conditions: results were split. Cue-induced anxiety was lower on CBD in people with heroin use disorder (Hurd 2019) and alcohol use disorder (Hurzeler 2025), and speech anxiety was lower in people with Parkinson’s disease (de Faria 2020). A week of daily CBD had a partial effect in people at high risk of psychosis (Appiah-Kusi 2020). In 30 people with insomnia, those taking 150 mg a night for 2 weeks rated themselves calmer in their daily morning ratings than those on placebo, per a second paper on the same trial, while the trial’s anxiety measure, trait anxiety, showed no difference (Narayan 2024). Trials in 144 people with advanced cancer (Hardy 2023), 136 with hand osteoarthritis or psoriatic arthritis (Vela 2022), 78 with cocaine use disorder (Mongeau-Perusse 2022), 57 with alcohol use disorder taking CBD daily for 6 to 8 weeks (Bogenschutz 2026), 40 and 60 with Parkinson’s disease taking a low daily dose for 8 and 12 weeks (Kanjanarangsichai 2022; Mitarnun 2025) and 20 with brain tumors, stopped early, found no difference (Belgers 2026). In a pilot of 36 people having both knees replaced, anxiety scores after surgery were higher in the CBD groups, but the trial’s registry results show they were already higher before surgery, and no test was reported (Sideris 2026; see “Can CBD make anxiety worse?” below). Nayak 2024, the only trial that enrolled only women (50 with advanced breast cancer), had a mixed result: lower anxiety 2-4 hours after one dose only. No trial in our review tested perimenopause or health anxiety. See also CBD for sleep and CBD for pain.
- Depression: a 2026 Lancet Psychiatry review found no randomized trials of cannabinoids for depression as the main condition (Wilson 2026); this page covers anxiety only.
Why do CBD anxiety results vary so much?
Results vary because the studies differ. Most benefits came from single doses in lab tests, but some trials that gave CBD for days or weeks also found lower anxiety, such as daily oil in social anxiety disorder (Masataka 2019) and a 15-week trial in 178 people with anxiety disorders (Gundugurti 2024). Overall, those longer trials found a benefit less often than single-dose tests did. The doses, products, people studied and anxiety measures also differed.
The dose curve
In two speech tests, the middle dose lowered anxiety: 300 mg did, while 100 and 900 mg did not (Zuardi 2017), and 150 and 600 mg did not (Linares 2019). This is called an inverted U-shaped dose curve. A 2022 systematic review of 87 studies of single doses of CBD in people, mice and rats found that human studies using single oral doses of 300 to 600 mg tended to report lower anxiety. In most observations (70.3%), CBD had no effect on anxiety outcomes, no dosing recommendation was possible, and its authors say the results raise questions about the broad use of CBD as a drug for anxiety (Kwee 2022 review).
Placebo, size and length
Placebo groups improved too (Winkler 2025; Bogenschutz 2026). Studies had 10 to 180 people and ran one dose to 15 weeks; at least three enrolled only men (Crippa 2004; Fusar-Poli 2009; Linares 2019).
What people report vs what trials show
Posts in Reddit’s r/Anxiety describe mixed experiences with CBD. They reflect the products, doses and lengths of use people actually choose; what they can’t show is how much of a change comes from CBD rather than expectation, which placebo-controlled trials are built to separate. In clinic records of 279 adults prescribed CBD-rich products in Quebec, Canada, people who began with moderate or severe symptoms, anxiety included, had improved by 3 months, while anxiety scores of those who began with mild symptoms got worse. There was no comparison group, and the five authors work for or consult to the clinic network (Rapin 2021). A 2019 chart review covered 72 adults at one psychiatric clinic who took CBD alongside their usual care, 47 mainly for anxiety and 25 for poor sleep. Anxiety scores fell within the first month in 57 patients (79.2%) and stayed lower during the study. There was no comparison group, and its authors say controlled studies are needed (Shannon 2019).
How much CBD should I take for anxiety?
There is no official dose of CBD for anxiety, and studies have not worked out which amount suits a given person. In studies, daily-use trials gave adults about 16 to 1,200 mg a day, most of them 50 mg or more, and single-dose studies gave 50 to 900 mg by mouth or 32 mg inhaled (Gournay 2023; Bogenschutz 2026; Das 2013; Zuardi 2017; Sahinovic 2025). The only placebo-controlled trial with a fixed 50 mg daily dose reported an anxiety benefit for its 300 mg dose only (Gournay 2023). Three trials of about 16 to 30 mg a day for 8 to 12 weeks, in people with arthritis or Parkinson’s disease, found no difference in anxiety (Kanjanarangsichai 2022; Vela 2022; Mitarnun 2025). These are the amounts researchers used in studies. They are not dosing advice.
Forms and timing in the studies
Studies gave CBD by mouth (oil, capsules, tablets or solution) or under the tongue (Narayan 2024; Kanjanarangsichai 2022; Mitarnun 2025), except one fear-learning lab study that used inhaled, vaporized CBD (Das 2013; route in Blessing 2015, Table 2). None used gummies or topicals, and none compared forms; for lab tests of store-bought gummies, see product quality (Johnson 2025). One trial still found lower cue-induced anxiety 7 days after a 3-day course ended (Hurd 2019); no study tested how long a single dose lasts.
CBD vs THC, CBN and CBG for anxiety: what is known
CBD is not intoxicating; THC is. In a crossover study of 15 healthy men, THC raised anxiety and CBD did not (Fusar-Poli 2009). A 2020 systematic review covered 35 studies of THC, CBD or whole cannabis (17 in animals, 8 in people and 10 survey studies). It found that single doses of CBD reduced anxiety in both animals and people, without raising anxiety at higher doses, while THC commonly raised anxiety in human studies, especially at higher doses. It had few human studies, and its authors call for clinical trials in people with anxiety disorders (Sharpe 2020; one author reports consultancy payments from a cannabis manufacturer, which the paper says are unrelated to it). Products sold without THC can still contain it (NCCIH).
When CBD and THC are taken together, results are mixed. In a 2019 review of 16 studies (466 people), CBD reduced some effects of THC, including intense anxiety, in several studies but not in all (Freeman 2019). In a 2023 trial in 18 healthy adults, a brownie with 640 mg of CBD and 20 mg of THC raised anxiety more than one with 20 mg of THC alone (Zamarripa 2023).
No table study tested CBN, CBG, kava or L-theanine; a registered CBD, CBN and CBG study (NCT07821840) isn’t recruiting yet (Evidence Tracker). Outside the table, two placebo-controlled trials tested CBG or CBN alone, not CBD. In 34 healthy adults, a single 20 mg dose of CBG lowered self-rated anxiety compared with placebo, though a standard anxiety questionnaire score did not differ (Cuttler 2024, funded by a company that works with CBG). In a sleep trial of about 1,000 people, CBN at 25, 50 or 100 mg did not differ from placebo on anxiety over six weeks; the 100 mg dose lowered stress (Kolobaric 2024, funded by the product’s maker).
No placebo-controlled trial in our study table compared spectrum types. One registered trial with full-spectrum, single-compound and placebo groups has posted results but no test comparing the groups (NCT02548559, under generalized anxiety above). In one study without a placebo, 374 stressed volunteers used a CBD isolate oil and then a broad-spectrum oil; they rated both as helpful for stress and rated the broad-spectrum oil higher, though the fixed order may have affected the ratings and the oils’ maker supplied them (Faraj 2023). The one full-spectrum oil trial with a placebo in our study table found no difference (Winkler 2025; full-spectrum vs broad-spectrum vs pure CBD).
Has CBD been compared with anxiety medicines?
Two healthy-volunteer speech studies included a benzodiazepine. In one, people given clonazepam or the middle CBD dose both reported lower post-speech anxiety, and clonazepam was more sedating (Zuardi 2017); in the other, people given CBD reported lower post-speech anxiety, and only diazepam caused significant sedation (Zuardi 1993). No trial in our review compared CBD with SSRIs or benzodiazepines in people with anxiety disorders.
Is CBD safe? Side effects, drug interactions and who should avoid it
Talk to your doctor before using CBD, especially if you take any medicines or supplements, have liver problems, or have a health condition. In clinical studies, CBD was generally well tolerated, but the FDA says it can cause liver injury, drowsiness and drug interactions.
How can I get help with my anxiety?
About 19.1% of US adults had an anxiety disorder in the past year (NIMH, 2001-2003 data). A doctor or mental health professional can discuss proven treatments. Do not stop, reduce or change any prescribed medicine or treatment without talking to the doctor who prescribed it. If you are in crisis or thinking about harming yourself, call or text 988 to reach the 988 Suicide & Crisis Lifeline. In an emergency, call 911.
Side effects and liver effects
NCCIH lists decreased alertness, mood changes, less appetite and diarrhea. In a 2025 trial, 5.6% of healthy adults taking 5 mg of CBD per kg of body weight a day (about 350 mg a day for a 154 lb adult) had liver enzymes over 3 times normal within 4 weeks, versus none on placebo (Florian 2025). On dependence, the prescription CBD medicine’s prescribing information (section 9.3) reports no withdrawal signs in adults for 6 weeks after stopping a high daily dose taken for 28 days.
Can CBD make anxiety worse?
No trial in our review found significantly more anxiety on CBD than on placebo, but two leaned that way: anxiety improved more on placebo in Belgers 2026, and Hundal 2018 found a non-significant trend toward more anxiety. In a 2026 pilot of 36 people having both knees replaced (12 per group), anxiety scores, a secondary measure, were higher after surgery in the groups given prescription CBD solution, mainly at 800 mg; the abstract gives no p-value, and the trial’s registry results (NCT04749628) show the CBD groups’ scores were already higher before surgery (Sideris 2026). THC, which some CBD products contain without saying so (Johnson 2025), raised anxiety in a lab study (Fusar-Poli 2009).
Drug interactions
CBD can affect how other medicines work, which can cause serious side effects. Using CBD with alcohol or with medicines that cause drowsiness, such as some medicines for anxiety, panic, stress or sleep, raises the risk of sleepiness and injury.
| Medicine | What was found | Source |
|---|---|---|
| Citalopram or escitalopram | Higher citalopram levels in 6 patients; in lab tests CBD inhibited the liver enzymes (CYP3A4, CYP2C19) that break down citalopram | Anderson 2021 |
| Alcohol; sedating medicines for anxiety, panic, stress or sleep, such as benzodiazepines | More sedation and drowsiness | FDA |
| Warfarin (blood thinner), valproate (seizure medicine), tacrolimus and sirolimus (transplant medicines) | Most-reported interactions with cannabis or cannabinoids (THC, CBD) in a 2024 review | Nachnani 2024 |
Who should avoid CBD
Do not use CBD if you are pregnant, planning a pregnancy or breastfeeding. The FDA strongly advises against using CBD, THC or marijuana in any form during pregnancy or while breastfeeding.
CBD products are not for children. Keep them out of reach of children and pets. If a child swallows a CBD or THC product, call Poison Control at 1-800-222-1222 or get medical care right away.
For drug-test risk, see the FAQ.
How to check a CBD product’s quality
In January 2023 the FDA said it would not pursue rules allowing CBD in dietary supplements or foods and had not found enough evidence on how much CBD can be consumed, and for how long, before causing harm (FDA).
How to check a CBD product’s quality: read its certificate of analysis (COA) from an accredited third-party lab. See our guides to reading a COA and verifying the lab. Check that it is recent, matches the batch and lists CBD per serving, total THC per container (legal note) and contaminants.
Labels are not always accurate: a 2025 study that tested 97 hemp haircare, cosmetic and food products bought in 2020 found that 12.7% of those with a labeled amount were accurately labeled, and claims of third-party testing made no difference (Dowd 2025). In a 2025 test, 70% of 56 gummy products missed their labeled CBD amount by over 10% (Johnson 2025). A 2024 test of 202 US products found heavy metals in 44, residual solvents in 181 and pesticides in 30; only 1% to 3% of detections exceeded a regulatory limit (Gidal 2024, funded by Epidiolex maker Jazz Pharmaceuticals).
Frequently asked questions
What should you look for in a CBD product?
No trial in our review compared forms or brands of CBD for anxiety. Look for a recent, batch-matched COA from an accredited lab (how to read a COA) rather than relying on the label, because product labels are not always accurate (Dowd 2025).
Should you take CBD for anxiety?
Research is mixed and low-certainty. In our review, most earlier studies, largely single doses in lab tests, found lower anxiety, while most placebo-controlled trials published since 2022, more of them daily doses, found no difference. If you are considering CBD, read the safety section first, especially if you take any medicines.
How long does CBD take to kick in?
In one trial with a mixed result, anxiety was lower 2 to 4 hours after a single dose (Nayak 2024), but no trial in our review measured how quickly an effect begins. Inhaled CBD peaks in the blood faster than swallowed CBD (Millar 2018). About 6% of swallowed CBD reaches the blood when fasting; a high-fat meal raises that about fourfold (Perucca 2020).
What are the potential side effects of smoking CBD?
No study in our review tested smoked CBD; the one inhaled study used vaporized CBD (Das 2013). Hemp flower also contains some THC, which raised anxiety in a lab study where CBD did not (Fusar-Poli 2009). The side effects and FDA warnings in the safety section still apply (safety).
Will CBD show up on a drug test?
Some CBD products contain THC, even when the label says they don’t. Using CBD can lead to a positive drug test. In a 2025 test, 39% of CBD gummy products contained THC (Johnson 2025; see the legal note).
The bottom line: what the research supports and what it does not
What supports CBD for anxiety: 12 of the 38 placebo-controlled trials in our review found a benefit, most of them after a single dose, and 4 more had mixed or partial results; some trials of CBD taken for days or weeks also found lower anxiety, including a 15-week trial in people with anxiety disorders. What does not: most trials published since 2022, more of them daily doses, found no difference from placebo, and the overall evidence is low-certainty. Separately from whether it works, CBD can interact with medicines and is not for everyone; see the safety section, including how to get help with anxiety. More: CBD health research.
How we researched this
We do not sell or recommend products on this page. Every study cited was checked at PubMed or the publisher. Figures from Cannabidiol Life’s Evidence Tracker show the date and source used.
On October 23, 2026, we checked 134 sources (126 plus 8 added during verification), cite 50, and replaced the old page’s 17 references. On November 13, 2026, we screened the further papers on CBD and anxiety held in Cannabidiol Life’s research library (5,059 PubMed records). Our search found 723 papers on CBD or medical cannabis and anxiety that were not yet in our review; we checked 47 of them at PubMed and added 16 studies that met this page’s rules: 8 placebo-controlled trials in the study table and 8 other studies and reviews in the text. That day we also added 17 more sources from our October research: reviews and meta-analyses, one chart review of clinic patients and one trial’s results posted on ClinicalTrials.gov. Each reported a benefit or a favorable signal for anxiety, in some cases for all cannabinoids or related compounds rather than CBD alone. They are a selection, not a full list of the reviews on CBD and anxiety.
Important safety and legal information
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have about a medical condition.
These statements have not been evaluated by the Food and Drug Administration. Hemp-derived CBD products are not intended to diagnose, treat, cure, or prevent any disease.
For side effects, drug interactions, pregnancy and breastfeeding, and crisis support, see the safety section above.
Is CBD legal? Federal law is changing. Under the 2018 Farm Bill definition, hemp (including hemp-derived CBD) is cannabis with no more than 0.3% delta-9 THC by dry weight, and it is not a controlled substance. A new federal definition applies in two steps (section 781 of Public Law 119-37, with start dates set by Public Law 119-103). Starting November 12, 2026, hemp products that contain cannabinoids the plant cannot produce naturally no longer count as hemp. Starting December 11, 2026, the rest of the definition applies. It counts total THC, including THCA, and a finished hemp product such as a CBD oil or gummy qualifies as hemp only if each container holds no more than 0.4 mg of total THC and similar cannabinoids, and contains no cannabinoids that were synthesized or manufactured outside the plant. Some full-spectrum CBD products contain more THC than that. State laws differ and can be stricter. This is general information, not legal advice.
Sources
- Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1 Suppl):82-88. PubMed
- Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. PubMed
- Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimaraes FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019;41(1):9-14. PubMed Industry ties: CBD supplied free by STI-Pharm; several authors are co-inventors on a related CBD patent.
- US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). FDA Q&A page (content current as of 07/16/2024). Link
- Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021;41(5):525-533. PubMed
- US Food and Drug Administration. What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. FDA Consumer Update (content current as of 03/05/2020). Link
- Dowd AN, Zamarripa CA, Sholler DJ, et al. Cannabinoid Content and Label Accuracy of Various Hemp-Derived Haircare, Cosmetic, and Edible Products Available at Retail Stores and Online in the United States. Cannabis Cannabinoid Res. 2025;10(6):719-725. PubMed
- Johnson ED, Kilgore MW, Stafford M, et al. Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res. 2025;10(6):710-718. PubMed
- Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836. PMC
- Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417-426. PubMed
- Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66(1):95-105. PubMed
- Wilson J, Dobson O, Langcake A, Mishra P, Bryant Z, Leung J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(4):304-315. Erratum in: Lancet Psychiatry. 2026;13(8):e11. PubMed
- Raminelli AO, Simei JLQ, Guimaraes FS, Zuardi A, Hallak JEC, Crippa JA, et al. Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. Cannabis Cannabinoid Res. 2025;10(6):655-672. PubMed
- Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PubMed
- National Center for Complementary and Integrative Health (NCCIH), NIH. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. NCCIH web page (Last Updated: November 2019, as displayed 2026-10-23). Link
- Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-130. PubMed
- Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019;10:2466. PubMed
- Kwee CM, Baas JM, van der Flier FE, Groenink L, Duits P, Eikelenboom M, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Eur Neuropsychopharmacol. 2022;59:58-67. PubMed
- Gundugurti PR, Banda N, Yadlapalli SSR, Narala A, Thatikonda R, Kocherlakota C, et al. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. Asian J Psychiatr. 2024;97:104073. PubMed Industry ties: the CEO and staff of the product’s developer, Leiutis Pharmaceuticals, are authors.
- Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013;226(4):781-792. PubMed
- Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol. 2017;8:259. PubMed Industry ties: CBD supplied free by BSPG-Pharm; several authors are co-inventors on a related CBD patent.
- Arndt DL, de Wit H. Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults. Cannabis Cannabinoid Res. 2017;2(1):105-113. PubMed
- Hundal H, Lister R, Evans N, Antley A, Englund A, Murray RM, et al. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol. 2018;32(3):276-282. PubMed
- Bloomfield MAP, Yamamori Y, Hindocha C, Jones APM, Yim JLL, Walker HR, et al. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology (Berl). 2022;239(5):1539-1549. PubMed
- Leen-Feldner EW, Bynion TM, Eglit GML, Bonn-Miller MO, Gournay LR, Feldner MT. A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge. Psychopharmacology (Berl). 2025;242(7):1515-1527. PubMed Industry ties: sponsored by Canopy Growth Corporation, which employs three of the six authors.
- Stanley TB, Ferretti ML, Bonn-Miller MO, Irons JG. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students. Cannabis Cannabinoid Res. 2023;8(6):1090-1099. PubMed Industry ties: one author was affiliated with Canopy Growth Corporation.
- Rudisill TM, Innes KK, Wen S, Haggerty T, Smith GS. The effects of cannabidiol on subjective states, cognition, and psychomotor function in healthy adults: A randomized clinical trial. Fundam Clin Pharmacol. 2023;37(3):663-672. PubMed
- Gournay LR, Ferretti ML, Bilsky S, Vance E, Nguyen AM, Mann E, et al. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial. Psychopharmacology (Berl). 2023;240(10):2147-2161. PubMed
- Winkler A, Meis AC, Hermann C. Placebo effects in a RCT assessing 30 days of low dose Cannabidiol (CBD) treatment for psychological distress in stressed students at risk for depression. J Cannabis Res. 2025;7(1):98. PubMed
- Bolsoni LM, Crippa JAS, Hallak JEC, Guimaraes FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology (Berl). 2022;239(5):1499-1507. PubMed
- Gournay LR, Ferretti ML, Nguyen AM, Bilsky S, Shields GS, Mann E, et al. The effects of acute versus repeated cannabidiol administration on trauma-relevant emotional reactivity: A double-blind, randomized, placebo-controlled trial. J Trauma Stress. 2024;37(6):946-958. PubMed Industry ties: grant from Canopy Growth Corporation; one author affiliated with Charlotte’s Web.
- Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019;176(11):911-922. PubMed Industry ties: the trial registry lists Jazz Pharmaceuticals as a collaborator.
- de Faria SM, de Morais Fabricio D, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020;34(2):189-196. PubMed
- Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020;237(4):1121-1130. PubMed
- Mongeau-Perusse V, Rizkallah E, Morissette F, Brissette S, Bruneau J, Dubreucq S, et al. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial. J Addict Med. 2022;16(5):521-526. PubMed
- Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol. 2023;41(7):1444-1452. PubMed
- Nayak MM, Chai P, Catalano PJ, Pirl WF, Tulsky JA, Tung SC, et al. Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(12):e2450391. PubMed
- Hurzeler T, Logge W, Watt J, McGregor IS, Suraev A, Haber PS, et al. Cannabidiol alters psychophysiological, craving and anxiety responses in an alcohol cue reactivity task: A cross-over randomized controlled trial. Alcohol Clin Exp Res (Hoboken). 2025;49(2):448-459. PubMed
- Belgers V, Rottgering JG, Gorter M, Blom MEC, Thomassen B, Douw L, et al. Cannabidiol for anxiety and depressive symptoms in primary brain tumors: Results from an early-terminated, placebo-controlled, crossover randomized clinical trial. Neurooncol Pract. 2026;13(5):1023-1024. PubMed
- Bogenschutz MP, Blessing E, Dgheim D, Cho D, Zhang J, Laska EM, et al. Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials. Alcohol Clin Exp Res (Hoboken). 2026;50(1):e70212. PubMed Industry ties: Tilray Canada supplied the CBD and part-funded the drug-level analysis (main funding: NIAAA grants).
- de Andrade Silva S, Velozo C, de Almeida Souto Montenegro L, de Sousa WV, da Cunha Isaltino M, de Fatima Formiga Melo Diniz M, et al. Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. J Endod. 2024;50(12):1698-1704. PubMed
- National Institute of Mental Health (NIMH). Any Anxiety Disorder (statistics page). NIMH web page. Link
- Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1070-1078. PubMed
- Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, Tegeler K, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. PubMed
- US Food and Drug Administration (Janet Woodcock, MD, Principal Deputy Commissioner). FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward. FDA statement, January 26, 2023 (content current as of 01/26/2023). Link
- Gidal BE, Vandrey R, Wallin C, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol. 2024;15:1335441. PubMed Industry ties: funded by Jazz Pharmaceuticals, the maker of Epidiolex, which took part in the study; two authors are Jazz employees.
- Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. PubMed
- Perucca E, Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs. 2020;34(8):795-800. PubMed
- Jazz Pharmaceuticals. EPIDIOLEX (cannabidiol) oral solution: Full Prescribing Information (revised 5/2026; Medication Guide revised 7/2025). DailyMed (NLM), SPL set ID 8bf27097-4870-43fb-94f0-f3d0871d1eec, SPL version 35, published June 15, 2026. DailyMed
- Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. Depress Anxiety. 2020;37(8):801-811. PubMed
- Roberts L, Sorial E, Budgeon CA, Lee K, Preen DB, Cumming C. Medicinal cannabis in the management of anxiety disorders: A systematic review. Psychiatry Res. 2025;350:116552. PubMed
- McCartney D, Irwin C, Bawa Z, Palmer B, Sahinovic A, Delang N, et al. The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial. Sports Med Open. 2024;10(1):61. PubMed Industry ties: two authors report consulting fees from Medicinal Cannabis Industry Australia (study funded by a philanthropic University of Sydney centre).
- Sahinovic A, Lau NS, Sabag A, Gordon R, Cox AJ, Walker K, et al. The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial. Sports Med Open. 2025;11(1):96. PubMed Industry ties: two authors report consulting fees from Medicinal Cannabis Industry Australia (study funded by a philanthropic University of Sydney centre).
- Bell ER, Elias B, Gutierrez SM, Stewart LK. The Effects of an Acute Dose of Cannabidiol on Health and Two-Mile Time Trial Performance-A Pilot Study. Nutrients. 2025;18(1):29. PubMed
- Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. PubMed
- Kanjanarangsichai A, Mitarnun W, Mitarnun W, Pangwong W, Laoharattanahirun N, Kajornrith W, et al. Cannabidiol-enriched cannabis extraction product in Parkinson’s disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital. J Neurosci Rural Pract. 2022;13(4):663-668. PubMed
- Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024;20(5):753-763. PubMed Industry ties: supported by Cannvalate and the Barbara Dicker Brain Sciences Foundation; study treatments provided by Brains Bioceuticals.
- Narayan AJ, Hayley AC, Rose S, Di Natale L, Downey LA. The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial. Psychopharmacology (Berl). 2025;242(2):297-308. PubMed Second paper on the Narayan 2024 trial (daily mood ratings). Industry ties: study funding and study products from Brains Bioceuticals.
- Mitarnun W, Kanjanarangsichai A, Junlaor P, Kongngern L, Mitarnun W, Pangwong W, et al. Cannabidiol and cognitive functions/inflammatory markers in Parkinson’s disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial). Parkinsonism Relat Disord. 2025;135:107841. PubMed
- Sideris A, Chan W, Liu J, Della Valle AG, Baaklini L, Rodriguez J, et al. Effects of cannabidiol (CBD) oral solution in patients undergoing bilateral total knee arthroplasty: A randomized, controlled, parallel, triple blind, pilot study. J Pain. 2026;51:106477. PubMed
- Aviram J, Belobrov R, Grinapol S, Fruchter E. Efficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review. J Cannabis Res. 2026;8(1):89. PubMed Industry ties: one author is affiliated with, and another is a past employee of, a company that develops medical cannabis delivery systems.
- Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res. 2021;3(1):19. PubMed Industry ties: all five authors work for or consult to the medical cannabis clinic network where the study took place.
- Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696-712. PubMed
- Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, et al. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254752. PubMed
- Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep. 2024;14(1):16163. PubMed Industry ties: funded by CReDO Science, a company that works with CBG and whose founder is an author.
- Kolobaric A, Saleska J, Hewlings SJ, Bryant C, Colwell CS, D’Adamo CR, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep. Pharmaceuticals (Basel). 2024;17(8):977. PubMed Industry ties: funded by the product’s maker; six authors work for the company that ran the study.
- Faraj M, Dautrich T, Lundahl L, Marusak H. Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study. Med Cannabis Cannabinoids. 2023;6(1):138-147. PubMed Industry ties: the oils’ maker supplied the products and a discount to participants; one author is chief operating officer of the app company that ran the study.
- Fliegel DK, Lichenstein SD. Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety. Psychiatry Res Commun. 2022;2(4):100074. PubMed
- de Bode N, Kroon E, Sznitman SR, Cousijn J. The differential effects of medicinal cannabis on mental health: A systematic review. Clin Psychol Rev. 2025;118:102581. PubMed
- Jantsch J, Wickert F, Fraga GF, de Fraga LS, Duran-Carabali LE, Guedes RP. Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies. Mol Psychiatry. 2026;31(11):6676-6692. PubMed
- Kwee CMB, Leen NA, Van der Kamp RC, Van Lissa CJ, Cath DC, Groenink L, et al. Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2023;72:79-94. PubMed
- Narayan AJ, Downey LA, Manning B, Hayley AC. Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance. Neurosci Biobehav Rev. 2022;143:104941. PubMed
- Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2020;60(1):253-261. PubMed
- Perez JG, LaMontagne LG, Garcia GA, Vaddiparti K, Gupta PS, Churba BZ, et al. Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review. Med Cannabis Cannabinoids. 2025;8(1):219-237. PubMed
- Coelho CF, Vieira RP, Araujo-Junior OS, Lopes-Martins PSL, Dos Santos LG, Dias LD, et al. The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials. Life (Basel). 2024;14(11):1373. PubMed
- Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis. J Psychiatr Res. 2020;129:257-264. PubMed
- Wright M, Di Ciano P, Brands B. Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. Cannabis Cannabinoid Res. 2020;5(3):191-196. PubMed
- Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatr Serv. 2021;72(4):429-436. PubMed
- Andreoli G, Kasch C, Lindsay CE, Hofmann SG. Pharmacological strategies for treating social anxiety disorder in adults: a systematic review of studies published since 2015. Expert Rev Neurother. 2026;26(2):185-196. PubMed
- Schiele MA, Fagan HA, Baldwin DS, Domschke K. Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders. Psychother Psychosom. 2026;95(3):214-247. PubMed
- Gruber S (sponsor-investigator), McLean Hospital. Sublingual Cannabidiol for Anxiety (NCT02548559). ClinicalTrials.gov study record with posted results (results first posted March 27, 2026; not peer reviewed). Link
- Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, et al. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. J Psychopharmacol. 2022;36(12):1299-1314. PubMed
- Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. PubMed
- Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18(1):374. PubMed Industry ties: one author has received consultancy payments from a cannabis manufacturing company, which the paper says are unrelated to it.



